Soltani Arash, Shirzad Hadi, Panji Mohammad, Motevaseli Elahe, Mousavinezhad Seyyed Amin, Kalbasi Saeed
Research Center for Life & Health Sciences & Biotechnology of the Police, Directorate of Health, Rescue & Treatment, Police Headquarter, Tehran, Iran.
Department of Molecular Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Curr Org Synth. 2025 Jan 2. doi: 10.2174/0115701794335556241209175911.
α-Glucosidase inhibitors play an important role in the treatment of type 2 diabetes mellitus. Inhibitors of the latter enzyme that are available on the market created gastrointestinal side effects and achieve to a high potent and low side effect potent α-glucosidase inhibitors is a valuable target for medicinal chemists.
In this study, derivatives of benzimidazole-phenoxy-1,2,3-triazole-benzyl skeleton were introduced as new α-glucosidase inhibitors.
Twelve derivatives 8a-l of target scaffold were synthesized via simple chemical re-actions with a yield between 65 and 88%. The in vitro α-glucosidase inhibition activities of these compounds was evaluated against yeast form of this enzyme. After the determination of most potent compound, the interaction of this compound with α-glucosidase was evaluated in vitro by kinetic study and in silico by docking study. Drug-likeness, pharmacokinetics, and toxicity profiles of the most potent compound were predicted by an online software.
Anti-α-glucosidase assay demonstrated that all synthesized derivatives 8a-l were more potent that standard inhibitor acarbose. Representatively, 2-(4-((1-benzyl-1H-1,2,3-triazol-4-yl)methoxy)phenyl)-1H-benzo[d]imidazole (compound 8a) as the most potent derivative was 150-times more potent than positive control. Kinetic study of compound 8a revealed that this compound is an uncompetitive inhibitor against α-glucosidase. Furthermore, molecular docking study showed that compound 8a with favorable binding energy attached to important residues in the α-glucosidase active site. This compound also can be an oral drug with favorable toxicity profile.
Benzimidazole-phenoxy-1,2,3-triazole-benzyl derivatives 8a-l synthesized and evaluated for anti-α-glucosidase activity. All these compounds were excellent α-glucosidase inhibitor, and compound 8a demonstrated the most significant inhibition effect when com-pared with positive control.
α-葡萄糖苷酶抑制剂在2型糖尿病的治疗中发挥着重要作用。市场上现有的后一种酶的抑制剂会产生胃肠道副作用,因此开发高效低毒的α-葡萄糖苷酶抑制剂是药物化学家的一个重要目标。
本研究引入苯并咪唑-苯氧基-1,2,3-三唑-苄基骨架衍生物作为新型α-葡萄糖苷酶抑制剂。
通过简单化学反应合成了12种目标支架衍生物8a-l,产率在65%至88%之间。针对该酶的酵母形式评估了这些化合物的体外α-葡萄糖苷酶抑制活性。在确定最有效的化合物后,通过动力学研究在体外和通过对接研究在计算机模拟中评估了该化合物与α-葡萄糖苷酶的相互作用。使用在线软件预测了最有效化合物的类药性、药代动力学和毒性概况。
抗α-葡萄糖苷酶试验表明,所有合成的衍生物8a-l均比标准抑制剂阿卡波糖更有效。代表性地,作为最有效衍生物的2-(4-((1-苄基-1H-1,2,3-三唑-4-基)甲氧基)phenyl)-1H-苯并[d]咪唑(化合物8a)比阳性对照强150倍。化合物8a的动力学研究表明,该化合物是α-葡萄糖苷酶的非竞争性抑制剂。此外,分子对接研究表明,具有有利结合能的化合物8a附着在α-葡萄糖苷酶活性位点的重要残基上。该化合物也可以是一种具有良好毒性概况的口服药物。
合成并评估了苯并咪唑-苯氧基-1,2,3-三唑-苄基衍生物8a-l的抗α-葡萄糖苷酶活性。所有这些化合物都是优秀的α-葡萄糖苷酶抑制剂,与阳性对照相比,化合物8a表现出最显著的抑制效果。